Catalog No.
RHG07802
Species reactivity
Human, Monkey
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Tested applications
IF: 1:200-1:1000, IHC: 1:200-1:1000, WB: 1:500-1:2000
Target
BPK, Tyrosine-protein kinase BTK, AGMX1, Agammaglobulinemia tyrosine kinase, Bruton tyrosine kinase, BTK, ATK, B-cell progenitor kinase
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q06187
Applications
IF, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3R23
Immunohistochemical Study of the Localization of Ibrutinib-Protein Conjugates in the Rat Gastrointestinal Tract., PMID:40535471
Marginal Zone Lymphoma: Treatment Update With a Focus on Systemic Approaches., PMID:40517548
Advances in the Management of Relapsed/Refractory CLL and Richter Transformation., PMID:40517442
Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia., PMID:40515863
Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies., PMID:40475129
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia., PMID:40472329
Antibody-Directed Cell Internalization of Targeted Covalent Europium Tag Enables In Situ Kinase Labeling and Inductively Coupled Plasma Mass Spectrometry (ICP-MS) Quantification., PMID:40470552
Hitting the Therapeutic Bullseye with Targeted Therapy for Patients with Chronic Lymphocytic Leukemia., PMID:40456120
Evaluating remibrutinib in the treatment of chronic spontaneous urticaria., PMID:40455080
Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors., PMID:40379542
The new era of primary immune thrombocytopenia management in adults: A narrative review of current and emerging treatments., PMID:40374446
Treatment of Anti-Myelin-Associated Glycoprotein (MAG) Antibody Neuropathy Using Zanubrutinib in a Patient With Waldenström Macroglobulinemia: A Clinical Vignette., PMID:40351903
New Frontiers in Multiple Sclerosis Treatment: From Targeting Costimulatory Molecules to Bispecific Antibodies., PMID:40332536
The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis., PMID:40327539
Efficacy and Safety of Rilzabrutinib in Patients With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Proof-of-Concept Phase II Clinical Trial., PMID:40317187
Chronic lymphocytic leukemia: what clinical progress have we seen in the last five years?, PMID:40314223
Treatment outcomes of BTK inhibitors and venetoclax with or without anti-CD20 monoclonal antibody in relapsed or refractory mantle cell lymphoma., PMID:40278919
Long term follow-up of MRD guided treatment of Ibrutinib plus Venetoclax for Relapsed CLL: phase 2 VISION/HO141 trial., PMID:40249856
Critical roles of chronic BCR signaling in the differentiation of anergic B cells into age-associated B cells in aging and autoimmunity., PMID:40249819
AMPLIFY: A second-generation BTK inhibitor for fixed-duration therapy in chronic lymphocytic leukemia., PMID:40220751
Doubling down: the new deal in the clinical management of double-refractory chronic lymphocytic leukaemia., PMID:40209064
[Update on marginal zone lymphoma classification, diagnosis and treatment in 2024]., PMID:40157832
Comparing novel treatments in chronic spontaneous urticaria: A critical appraisal of Bruton's tyrosine kinase inhibitors versus anti-cytokine biologics in clinical trials., PMID:40148228
Mantle cell lymphoma: from pathogenesis to treatment for 2024 and beyond., PMID:40146175
Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 2- Focus on Therapy., PMID:40084099
Update on the Treatment of Chronic Spontaneous Urticaria., PMID:40074986
Effects of orelabrutinib, a BTK inhibitor, on antibody-mediated platelet destruction in primary immune thrombocytopenia., PMID:40069128
BTK inhibitors enhance NKG2D ligand expression by regulating IL-10/STAT3 pathway in activated non-GCB diffuse large B-cell lymphoma cells., PMID:40029697
SOHO State of the Art Updates and Next Questions | Novel Immunotherapy Combinations for the Treatment of Indolent B-Cell Lymphoma., PMID:40011100
Strongyloides stercoralis infection in a DLBCL patient treated with rituximab and BTK inhibitor: A case report and literature review., PMID:39993065
Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma., PMID:39967670
BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL., PMID:39941922
Improving Treatment Options for Patients with Double Refractory CLL., PMID:39941798
Case report: Therapeutic use of bortezomib in a patient with Schnitzler syndrome., PMID:39935483
Molecular Mechanisms and Therapeutic Prospects of Immunotherapy and Targeted Therapy in Primary Central Nervous System Lymphoma., PMID:39912261
Pseudomonas aeruginosa sepsis with sacroiliitis in X-linked agammaglobulinaemia., PMID:39900389
Challenges in the Management of a Difficult-to-Treat Patient With Hairy Cell Leukemia: A Case Report., PMID:39886728
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial., PMID:39883943
Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction., PMID:39846984
From phenotypic to molecular diagnosis: Insights from a clinical immunology service focused on inborn errors of immunity in Colombia., PMID:39836844
The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics., PMID:39827471
Increased Phosphorylation of Intracellular Signaling Molecules Indicates Continuous Activation of Human Autoreactive B-Cells., PMID:39821328
Inhibition of Bruton's tyrosine kinase restricts neuroinflammation following intracerebral hemorrhage., PMID:39744694
Molecular Profiling Identifies CD49d and CD79b as Predictive Markers for Acquired Acalabrutinib Resistance in Patients With Chronic Lymphocytic Leukemia., PMID:39716442
One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID-19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic., PMID:39711119
[Updates on hairy cell leukemia (HCL) and HCL-like disorders]., PMID:39710534
Differential Cardiotoxicity of Ibrutinib Versus Chemoimmunotherapy in Chronic Lymphocytic Leukemia: A Population-Based Study., PMID:39685948
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?, PMID:39644005
[Single-center study of COVID-19 in patients with chronic lymphocytic leukemia]., PMID:39622756
Therapies for Chronic Spontaneous Urticaria: Present and Future Developments., PMID:39598410
For research use only. Not for human or drug use.
